June 2010
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p11
The article reports on the approval of the U.S. Food and Drug Administration (FDA) of Dendreon Corp.'s Provenge (sipuleucel-T), a therapy for prostate cancer.


Related Articles

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p4 

    The article offers news briefs related to various drugs used for the treatment of cancer. The firm GlaxoSmithKline has submitted a new application to the authorities in Japan for approval to sell the drug Tykerb which is used for treating breast cancer. Dendreon Corp. is about to secure the...

  • HOW TO SAVE A LIFE. Trinidad, Alison // Jacksonville Magazine;May2011, Vol. 27 Issue 5, p34 

    The article offers brief information on Provenge life-saving technology for patients with advanced prostate cancer from Dendreon Corp.

  • Options put squeeze on prostate cancer. Belden, Heidi // Drug Topics;5/7/2007, Vol. 151 Issue 9, p28 

    The article discusses advances in the treatment of prostate cancer. The U.S. Food & Drug Administration's Office of Cellular, Tissue and Gene Therapies Advisory Committee has approved Dendreon Corp.'s Biologics License Application for sipuleucel-T based on available safety and efficacy data....

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.

  • Specialty Drug Maker Starts Seal Beach Production. Reed, Vita // Orange County Business Journal;7/25/2011, Vol. 34 Issue 30, p3 

    The article reports that the manufacturing plant of Dendreon Corp. in Seal Beach, California is open for business. In this city, the drug maker will produce a highly specialized prostate cancer drug called Provenge. According to senior vice president of operations Heidi Hagen, the plant received...

  • Dendreon reports positive phase III trial results for Provenge.  // PharmaWatch: Cancer;February 2004, Vol. 3 Issue 2, p11 

    Reports on the results of Dendreon Corp.'s phase II trial for Provenge in the treatment of prostate cancer. Mechanism of action.

  • Dendreon Raising $356M for Provenge, Launch.  // Bioworld Week;12/21/2009, Vol. 17 Issue 51, p2 

    The article reports on the 15 million shares of stocks offered by Dendreon Corp. in Seattle, Washington. It states that proceeds of the sale will be used to fund the urgent construction of several new manufacturing facilities within the U.S. in preparation for the launching of Provenge which is...

  • Medicare Panel Backs Provenge; Dendreon Gains. Young, Donna // BioWorld Today;11/19/2010, Vol. 21 Issue 225, p1 

    The article reports that Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) has commended Dendreon Corp. for its Provenge (sipuleucel-T) drug for prostate cancer. MEDCAC issued high marks to Provenge for avoiding or reducing the burdens of anticancer therapy while maintaining...

  • FDA approves prostate cancer "vaccine" treatment. Tanne, Janice Hopkins // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/8/2010, Vol. 340 Issue 7754, p998 

    The article reports on the approval of Provenge (sipuleucel-T), a therapeutic vaccine against cancer manufactured by Seattle, Washington-based Dendreon, by the U.S. Food and Drug Administration (FDA).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics